Absci (ABSI) Capital Expenditures (2020 - 2026)
Absci (ABSI) posted Capital Expenditures of $30000.0 for Q1 2026, up 129.13% sequentially from -$103000.0 in Q4 2025, and up 20.0% YoY from $25000.0 in Q1 2025.
Analysis
Absci (ABSI) Capital Expenditures (2020 - 2026) Analysis & Trends
Absci has reported Capital Expenditures for 7 years, with the latest figure at $30000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 20.0% year-over-year to $30000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 159.21% YoY) and the FY2025 annual result came in at $1.1 million, up 174.01% from the prior year.
- Capital Expenditures grew to $30000.0 in Q1 2026 per ABSI's latest filing, from -$103000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $13.6 million in Q3 2022 and troughed at -$15.6 million in Q4 2022.
- A 5-year average of $101866.7 and a median of $30000.0 in 2026 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 10356.25% in 2022, down 321.69% in 2022.
- Over 5 years, Capital Expenditures stood at -$15.6 million in 2022, then surged by 99.5% to -$78000.0 in 2023, then jumped by 525.64% to $332000.0 in 2024, then plunged by 131.02% to -$103000.0 in 2025, then soared by 129.13% to $30000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $30000.0, -$103000.0, and $962000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | -103,000.00 |
| Sep 30, 2025 | 962,000.00 |
| Jun 30, 2025 | 223,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Sep 30, 2024 | 48,000.00 |
| Jun 30, 2024 | 337,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Sep 30, 2023 | 307,000.00 |
| Jun 30, 2023 | 256,000.00 |
| Mar 31, 2023 | 280,000.00 |
| Dec 31, 2022 | 560,000.00 |
| Sep 30, 2022 | 4.87 Mn |
| Jun 30, 2022 | 3.89 Mn |
| Mar 31, 2022 | 6.86 Mn |
| Dec 31, 2021 | 8.32 Mn |
| Sep 30, 2021 | 5.62 Mn |